UroGen Pharma (URGN) director converts 2,000 RSUs into 2,000 ordinary shares

Rhea-AI Filing Summary

UroGen Pharma Ltd. director exercises RSUs into shares. On February 26, 2025, director James A. Robinson Jr. exercised 2,000 Restricted Stock Units, each representing a right to receive one ordinary share. This conversion resulted in the acquisition of 2,000 ordinary shares at a stated price of $0.00 per share.

After these transactions, his reported holdings increased to 4,000 Restricted Stock Units and 4,000 ordinary shares, all held directly. The activity reflects an equity award conversion rather than an open-market purchase or sale.

Insider Trade Summary

2,000 shares exercised/converted

Mixed 2 txns

Insider Robinson James A. Jr.

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit	2,000	$0.00	--
Exercise	ordinary shares	2,000	$0.00	--

Holdings After Transaction: Restricted Stock Unit — 4,000 shares (Direct); ordinary shares — 4,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Robinson James A. Jr.

(Last) (First) (Middle)

400 ALEXANDER PARK DRIVE

(Street)

PRINCETON NJ 08540

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
UroGen Pharma Ltd. [ URGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
ordinary shares	02/26/2025		M		2,000	A	(1)	4,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	02/26/2025		M			2,000	(1)	(1)	Ordinary Shares	2,000	$0	4,000	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer

	/s/ Jason D. Smith, Attorney-in-Fact	02/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did UroGen Pharma (URGN) report for James A. Robinson Jr.?

UroGen Pharma reported that director James A. Robinson Jr. exercised 2,000 Restricted Stock Units into 2,000 ordinary shares. The transaction reflects a derivative security conversion at a stated price of $0.00 per share, not an open-market stock purchase or sale.

How many UroGen Pharma (URGN) shares did the director acquire in this Form 4?

The director acquired 2,000 ordinary shares of UroGen Pharma through the exercise of 2,000 Restricted Stock Units. Each RSU represents a contingent right to receive one ordinary share, resulting in a one-for-one conversion into common equity.

What are Restricted Stock Units in the UroGen Pharma (URGN) Form 4?

In this filing, each Restricted Stock Unit represents a contingent right to receive one ordinary share of UroGen Pharma. When the RSUs are exercised or vest, they convert into ordinary shares on a one-for-one basis as part of the director’s equity compensation.

Did the UroGen Pharma (URGN) director buy shares on the open market?

No, the director did not buy shares on the open market. The Form 4 shows an exercise or conversion of 2,000 Restricted Stock Units into 2,000 ordinary shares at a stated price of $0.00 per share, reflecting an equity award transaction.

What is the director’s UroGen Pharma (URGN) ownership after this Form 4?

After the reported transactions, the director’s holdings are 4,000 Restricted Stock Units and 4,000 ordinary shares of UroGen Pharma. All positions are indicated as being held directly, according to the ownership information disclosed in the Form 4.

Is the UroGen Pharma (URGN) Form 4 transaction classified as an acquisition or disposal?

The Form 4 classifies both transactions as acquisitions through exercise or conversion of derivative securities. The reporting uses transaction code M, indicating the exercise of 2,000 Restricted Stock Units into 2,000 ordinary shares rather than a sale or other disposition.